ASLAN Pharmaceuticals Pte Ltd Opens China Office
Singapore, 8 April 2016 – ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced the opening of its office in Shanghai.
This is ASLAN’s first office in China, and will complement the company’s existing presence in Singapore and Taiwan. The office will be responsible for managing local clinical and manufacturing activities, and will strengthen ASLAN’s ability to address the significant disease burden of tumour types more common in China, such as gastric cancer and cholangiocarcinoma.
ASLAN has been collaborating with local partners in China for manufacturing and clinical activities since 2012. The Company recently received Clinical Trial Approval and will be starting its first clinical trial for its lead drug, varlitinib. ASLAN was also named ‘Asian Biotech of the Year’ at the 2016 BioPharma Asia Awards for its unique and creative approach to drug development processes.
This is ASLAN’s first office in China, and will complement the company’s existing presence in Singapore and Taiwan. The office will be responsible for managing local clinical and manufacturing activities, and will strengthen ASLAN’s ability to address the significant disease burden of tumour types more common in China, such as gastric cancer and cholangiocarcinoma.
ASLAN has been collaborating with local partners in China for manufacturing and clinical activities since 2012. The Company recently received Clinical Trial Approval and will be starting its first clinical trial for its lead drug, varlitinib. ASLAN was also named ‘Asian Biotech of the Year’ at the 2016 BioPharma Asia Awards for its unique and creative approach to drug development processes.